Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments

Frontiers in Cardiovascular Medicine

article

Anais Audebrand¹  Laurent Désaubry¹  Canan G. Nebigil¹ 

[1] Laboratory of CardioOncology and Therapeutic Innovation

关键词: GPCRs;    cardiotoxicity;    melatonin;    ghrelin;    galanin;    apelin;    prokineticin;    cannabidiol;   

DOI  :  10.3389/fcvm.2019.00194

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Novel anticancer medicines, including targeted therapies and immune checkpoint inhibitors, have greatly improved the management of cancers. However, both conventional and new anticancer treatments induce cardiac adverse effects, which remain a critical issue in clinic. Cardiotoxicity induced by anti-cancer treatments compromise vasospastic and thromboembolic ischemia, dysrhythmia, hypertension, myocarditis, and cardiac dysfunction that can result in heart failure. Importantly, none of the strategies to prevent cardiotoxicity from anticancer therapies is completely safe and satisfactory. Certain clinically used cardioprotective drugs can even contribute to cancer induction. Since G protein coupled receptors (GPCRs) are target of forty percent of clinically used drugs, here we discuss the newly identified cardioprotective agents that bind GPCRs of adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin and cannabidiol. We hope to provoke further drug development studies considering these GPCRs as potential targets to be translated to treatment of human heart failure induced by anticancer drugs.

【 授权许可】

CC BY